- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04985344
Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol (PPP)
Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol: A Randomized Placebo-controlled Trial. PPP
By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out.
The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory.
Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out.
The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory.
Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.
The combination of the targeted reactivation of the traumatic memory and the intake of an agent that decreases the reconsolidation can thus disrupt the recall of unwanted memories and thus serve as a treatment for people suffering from traumatic memories, such as in PTSD.
Since stimulation of β-noradrenergic receptors facilitates the consolidation of memories as well as their re-consolidation, an antagonist of these receptors, propranolol, has generated considerable interest as a treatment to alleviate emotional and traumatic memories in individuals with PTSD.
In adults diagnosed with long-standing PTSD two 6-week, double-blind, placebocontrolled, randomised clinical trials, one in 60 subjects and the other in 67 have shown promising results. PTSD participants who actively recalled their traumatic event under the influence of propranolol once a week for up to 6 weeks showed a substantial decrease in symptom ratings compared with placebo. Thus, all of this data led the team to propose a comparable design study in children with PTSD
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Philippe Birmes, PH
- Phone Number: +33 05 34 55 75 00
- Email: birmes.p@chu-toulouse.fr
Study Locations
-
-
-
Toulouse, France, 31059
- Recruiting
- Toulouse University Hospital
-
Contact:
- Philippe BIRMES, PH
- Phone Number: +33 5 34 55 75 00
- Email: birmes.p@chu-toulouse.fr
-
Principal Investigator:
- Philippe BIRMES, PH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children aged 7-12 years
- CPTS-RI total score ≥40
- Primary diagnosis of PTSD (6 months or more after the traumatic event)
- Heart rate ≥ 55 bpm
- Systolic blood pressure ≥ 95 mm Hg
- Affiliation to a social security scheme
- Written consent signed by the parents/holders of parental authority and the investigator
- Acceptance of the protocol by the child-Child and Parents/Holders of parental authority fluent in French
Exclusion Criteria:
- Age<7 years or ≥13 years
- Children whose parents have been deprived of their authority
- Contraindication to propranolol (cardiogenic shock, sinus bradycardia, hypotension (< fifth percentile oscillometric or <2SD) (Banker et al., 2016 - see APPENDIX 1), greater than first-degree heart block, heart failure, bronchial asthma and hypersensitivity to propranolol hydrochloride)
- Concurrent medication with possible interactions with propranolol (cf 8.2)
- Concurrent psychotropic drugs that have been shown to be effective in improving symptoms of PTSD (Antidepressants, atypical antipsychotics, mood stabilizers)
- Concurrent psychotherapy (>1 structured session/month declared by the clinician who follows the child)
- Current active psychosis, anorexia nervosa, bulimia nervosa, binge-eating disorder, attention-deficit hyperactivity disorder, autism spectrum disorder
- Children with psoriasis
- Children with a predisposition to hypoglycemia
- Obsessive-compulsive disorders
- Bipolar Disorders
- Mental retardation,
- Traumatic brain injury (loss of consciousness > 10 minutes)
- Currently treated with a bradycardic drug
- Concurrent participation to another interventional study
- Renal or Hepatic Impairment
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Propranolol
Patient will receive oral propranolol
|
Child will receive oral propranolol (syrup).
The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
Other Names:
90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
|
Placebo Comparator: Placebo
Patient will receive oral placebo
|
90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
Child will receive oral placebo (syrup).
The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Child Post-Traumatic Stress Reaction Index/CPTS-RI
Time Frame: week 8
|
The main evaluation criterion will be the difference between the Child Post-Traumatic Stress Reaction Index/CPTS-RI total score administered at week 8 and week 0. The CPTS-RI is a scale comprised of 20 Likert-type items, intended for children from 6 to 16 years, which evaluates the symptoms of PTSD after exposure to various traumatic events.
Each item frequency is rated on a 5-point scale, from never (=0) to almost always (=4).
The global score consists of the sum of the 20 items and ranges from 0 to 80, with higher scores indicating higher PTSD symptom severity.
The time required for completion of the scale is 15-20 min.
A total score of 12-24 is associated with a mild level of PTSD, from 25-39 with a moderate level, from 40-59 with a severe level, and ≥60 with a very severe level.
|
week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Child Post-Traumatic Stress Reaction - Week 32 Index/CPTS-RI
Time Frame: week 32
|
The difference between the Child Post-Traumatic Stress Reaction Index/CPTS-RI total score at week 32 and week 8 .
The CPTS-RI is a scale comprised of 20 Likert-type items, intended for children from 6 to 16 years, which evaluates the symptoms of PTSD after exposure to various traumatic events.
Each item frequency is rated on a 5-point scale, from never (=0) to almost always (=4).
The global score consists of the sum of the 20 items and ranges from 0 to 80, with higher scores indicating higher PTSD symptom severity.
The time required for completion of the scale is 15-20 min.
A total score of 12-24 is associated with a mild level of PTSD, from 25-39 with a moderate level, from 40-59 with a severe level, and ≥60 with a very severe level.
|
week 32
|
Child Post-Traumatic Stress Reaction - Week 60 Index/CPTS-RI
Time Frame: week 60
|
The difference between the Child Post-Traumatic Stress Reaction Index/CPTS-RI total score administered at week 60 and week 8.
The CPTS-RI is a scale comprised of 20 Likert-type items, intended for children from 6 to 16 years, which evaluates the symptoms of PTSD after exposure to various traumatic events.
Each item frequency is rated on a 5-point scale, from never (=0) to almost always (=4).
The global score consists of the sum of the 20 items and ranges from 0 to 80, with higher scores indicating higher PTSD symptom severity.
The time required for completion of the scale is 15-20 min.
A total score of 12-24 is associated with a mild level of PTSD, from 25-39 with a moderate level, from 40-59 with a severe level, and ≥60 with a very severe level.
|
week 60
|
Child PTSD Checklist-Child version/CPC-C total score
Time Frame: Week 8
|
The difference between the Child PTSD Checklist-Child version/CPC-C total score administered at week 8 and week 0 on items 14-34.
The CPC-C includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment.
It is free in the public domain.
For scoring the CPC-C 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion.
Items 14-34 are PTSD symptom items.
|
Week 8
|
Child PTSD Checklist-Child version/CPC-C total score - Week 32
Time Frame: Week 32
|
The difference between the Child PTSD Checklist-Child version/CPC-C total score administered at week 8 and week 32 on items 14-34.
The CPC-C includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment.
It is free in the public domain.
For scoring the CPC-C 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion.
Items 14-34 are PTSD symptom items.
|
Week 32
|
Child PTSD Checklist-Child version/CPC-C total score - Week 60
Time Frame: Week 60
|
The difference between the Child PTSD Checklist-Child version/CPC-C total score administered at week 8 and week 60 on items 14-34.
The CPC-C includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment.
It is free in the public domain.
For scoring the CPC-C 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion.
Items 14-34 are PTSD symptom items.
|
Week 60
|
Child PTSD Checklist-Parent version/CPC-P total score - Week 32
Time Frame: Week 32
|
The difference between the Child PTSD Checklist-Parent version/CPC-P total score administered at week 8 and week 32 on items 14-34 (PTSD symptom items).
The CPC-P includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment.
It is free in the public domain.
For scoring the CPC-P, 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion.
Items 14-34 are PTSD symptom items.
|
Week 32
|
Child PTSD Checklist-Parent version/CPC-P total score - Week 60
Time Frame: Week 60
|
The difference between the Child PTSD Checklist-Parent version/CPC-P total score administered at week 8 and week 60 on items 14-34 (PTSD symptom items).
The CPC-P includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment.
It is free in the public domain.
For scoring the CPC-P, 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion.
Items 14-34 are PTSD symptom items.
|
Week 60
|
Child PTSD Checklist-Parent version/CPC-P total score
Time Frame: Week 8
|
The difference between the Child PTSD Checklist-Parent version/CPC-P total score administered at week 8 and week 0 on items 14-34 (PTSD symptom items).
The CPC-P includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment.
It is free in the public domain.
For scoring the CPC-P, 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion.
Items 14-34 are PTSD symptom items.
|
Week 8
|
Kiddie-SADS-Present and Lifetime Version DSM-5/K-SADS-PL-DSM5
Time Frame: week 8
|
The percentage of children without a current diagnosis of PTSD assessing with Kiddie-SADS-Present and Lifetime Version DSM-5/K-SADS-PL-DSM5.
The K-SADS-PL-DSM5 (November 2016) is a semi-structured diagnostic interview designed to collect information from the child or adolescent as well as their parents or other informants.
|
week 8
|
Current diagnosis of PTSD at Week 32
Time Frame: week 32
|
The percentage of children without a current diagnosis of PTSD assessing with Kiddie-SADS-Present and Lifetime Version DSM-5/K-SADS-PL-DSM5.
The K-SADS-PL-DSM5 (November 2016) is a semi-structured diagnostic interview designed to collect information from the child or adolescent as well as their parents or other informants.
|
week 32
|
Children Depression Inventory/CDI total score
Time Frame: week 8
|
The difference between the Children Depression Inventory/CDI total score administered at week 8 and week 0. The CDI is comprised of 27 items assessing self-reported symptoms of depression in children and adolescents 7-17 years of age.
|
week 8
|
Children Depression Inventory/CDI total score - Week 32
Time Frame: week 32
|
The difference between the Children Depression Inventory/CDI total score administered at week 8 and week 32.
The CDI is comprised of 27 items assessing self-reported symptoms of depression in children and adolescents 7-17 years of age.
|
week 32
|
Children Depression Inventory/CDI total score - Week 60
Time Frame: week 60
|
The difference between the Children Depression Inventory/CDI total score administered at week 8 and week 60.
The CDI is comprised of 27 items assessing self-reported symptoms of depression in children and adolescents 7-17 years of age.
|
week 60
|
Children's Sleep Habits Questionnaire/CSHQ Parent version total score
Time Frame: week 8
|
The difference between the Children's Sleep Habits Questionnaire/CSHQ Parent version total score administered at week 8 and week 0.The CSHQ was designed by clinical researchers at Brown University for children aged 4 through 12 years, to screen for the most common sleep problems in that age group.The first column 'of responses are scored: Usually=3, Sometimes=2, Rarely=1 for the entire questionnaire (except for the R=reversed items, which are considered to be "desirable" sleep behaviors, and thus scored in the opposite direction)
|
week 8
|
Children's Sleep Habits Questionnaire/CSHQ Parent version total score - Week 32
Time Frame: week 32
|
The difference between the Children's Sleep Habits Questionnaire/CSHQ Parent version total score administered at week 8 and week 32.The CSHQ was designed by clinical researchers at Brown University for children aged 4 through 12 years, to screen for the most common sleep problems in that age group.The first column 'of responses are scored: Usually=3, Sometimes=2, Rarely=1 for the entire questionnaire (except for the R=reversed items, which are considered to be "desirable" sleep behaviors, and thus scored in the opposite direction)
|
week 32
|
Children's Sleep Habits Questionnaire/CSHQ Parent version total score - Week 60
Time Frame: week 60
|
The difference between the Children's Sleep Habits Questionnaire/CSHQ Parent version total score administered at week 8 and week 60.The CSHQ was designed by clinical researchers at Brown University for children aged 4 through 12 years, to screen for the most common sleep problems in that age group.The first column 'of responses are scored: Usually=3, Sometimes=2, Rarely=1 for the entire questionnaire (except for the R=reversed items, which are considered to be "desirable" sleep behaviors, and thus scored in the opposite direction)
|
week 60
|
Comorbidity of other mental disorders
Time Frame: week 8
|
Using the K-SADS-PL DSM-5
|
week 8
|
Corsi Blocks task
Time Frame: week 8
|
The difference between the Corsi blocks task administered at week 0 and at week 8.
The Corsi Blocks task assesses the visuospatial component of working memory but uses various cognitive processes.
The subject needs to reproduce, in the same or reverse order, a sequence of pointing movements to different cubes shown by the rater
|
week 8
|
CGAS Children's Global Assessment Scale total score
Time Frame: week 32
|
The difference between the CGAS Children's Global Assessment Scale total score administered at week 8 and the score administered at week 32.
The Childrens Global Assessment Scale (CGAS) is a measure developed by Schaffer and colleagues at the Department of Psychiatry, Columbia University to provide a global measure of level of functioning in children and adolescents.
The measure provides a single global rating only, on scale of 0-100.
|
week 32
|
CGAS Children's Global Assessment Scale total score - Week 60
Time Frame: week 60
|
The difference between the CGAS Children's Global Assessment Scale total score administered at week 8 and the score administered at week 60.
The Childrens Global Assessment Scale (CGAS) is a measure developed by Schaffer and colleagues at the Department of Psychiatry, Columbia University to provide a global measure of level of functioning in children and adolescents.
The measure provides a single global rating only, on scale of 0-100.
|
week 60
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philippe Birmes, PH, Toulouse University Hospital
Publications and helpful links
General Publications
- Olliac B, Birmes P, Bui E, Allenou C, Brunet A, Claudet I, Sales de Gauzy J, Grandjean H, Raynaud JP. Validation of the French version of the Child Post-Traumatic Stress Reaction Index: psychometric properties in French speaking school-aged children. PLoS One. 2014 Dec 2;9(12):e112603. doi: 10.1371/journal.pone.0112603. eCollection 2014.
- Roullet P, Vaiva G, Very E, Bourcier A, Yrondi A, Dupuch L, Lamy P, Thalamas C, Jasse L, El Hage W, Birmes P. Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial. Neuropsychopharmacology. 2021 Aug;46(9):1643-1649. doi: 10.1038/s41386-021-00984-w. Epub 2021 Feb 21.
- Birmes P, Raynaud JP, Daubisse L, Brunet A, Arbus C, Klein R, Cailhol L, Allenou C, Hazane F, Grandjean H, Schmitt L. Children's enduring PTSD symptoms are related to their family's adaptability and cohesion. Community Ment Health J. 2009 Aug;45(4):290-9. doi: 10.1007/s10597-008-9166-3. Epub 2009 Jul 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Trauma and Stressor Related Disorders
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Propranolol
Other Study ID Numbers
- RC31/18/0471
- 2020-005956-39 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Active, not recruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on Propranolol Oral Product
-
Instituto do Cancer do Estado de São PauloRecruitingHepatocellular Carcinoma | Liver CancerBrazil
-
UAS Labs LLCCompleted
-
University Hospital, BordeauxCompleted
-
St George's, University of LondonRecruitingChronic Kidney Diseases | Heart Failure With Reduced Ejection Fraction | Hyperkalemia | ACE Inhibitor Induced Hyperkalaemia | Mineralocorticoid Resistant HyperkalemiaUnited Kingdom
-
Brigham and Women's HospitalUnknownChronic Kidney Diseases | HyperkalemiaUnited States
-
Peking Union Medical College HospitalUnknown
-
Xenon Pharmaceuticals Inc.CompletedHealthy VolunteersUnited Kingdom
-
Duke UniversityVifor PharmaCompletedEnd Stage Renal Disease | HyperkalemiaUnited States
-
National Cheng Kung UniversityNational Cheng-Kung University Hospital; Ministry of Science and Technology...Recruiting
-
Institut de Recherche pour le DeveloppementCompleted